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Abstract
Molecular assembly is a widely applied synthetic strategy for the
construction of multimolecular architecture at a nanoscale or
microscale that can simultaneously target numerous compo-
nents. Upon the control over size, shape, valency, etc., molecular
assembly can fulfill demands to regulate cellular responses even
cell fate by approaching different cellular sub-organelles as
potential cancer therapy.
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Introduction
Molecular assembly as a synthetic strategy can spontane-
ously form an array of well-defined nano/microstructures and
has attracted much attention in various applications.1 The
assembly process is mainly governed by weak non-covalent
bonds, such as ionic bonds (electrostatic interactions), hydrogen
bonds, van der Waals interactions, and hydrophobic interactions.
Although these forces are weak, their collective interactions can
create stable structures. The design of synthetic molecular
assembly often finds inspiration in Biology since they speak the
same language of life. For this very same reason, molecular
assembly can be designed to seamlessly integrate with the
biological environment, and it is considered as the most
promising approach to bionanotechnology.
Different from single molecules for which functional
application solely relies on molecular components, molecular
assembly offers a level of control over the characteristics of the
molecular components and over the interactions among them
leading to the most interesting applications at larger scale. At an
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early stage of development of bionanotechnology, molecular
assembly was mainly applied in pharmaceutical development of
drug delivery systems. Various nano/microstructures have been
developed for drug encapsulation to improve bioavailability and
controllability.2 Later, the expansion of imaging techniques
advanced the understanding of the kinetics and surface charac-
teristics of molecular assembly. Scientists found out that the
dynamic process of synthetic molecular assembly could stim-
ulate cellular responses via interface communication. Therefore,
constructing molecular assembly in the cell milieu is an
emerging bionanotechnology leading pharmaceutical develop-
ment into a new era.
The goal of this work is to highlight the most recent studies
on cellular sub-organelle-targeted molecular assembly compris-
ing design of targeted molecular assembly, exclusive features of
subcellular targeted molecular assembly, and the applications in
biomedicine for cancer treatment.
Plasma Membrane-targeting Molecular
Assembly
The plasma membrane has long been an attractive target in
the development of therapeutics regarding its multitude func-
tions.3 The bilayer structure separates and protects the interior of
the cell from the outside environment, serves as the attachment
surface for extracellular matrix, and mediates signaling processes
from outside into the cell interior. Targeting plasma membrane to
enhance its disruption has been established as the fundamental
strategy for the development of antibiotic drugs.4 Until the past
decade, targeting membrane proteins regulating signaling path-
ways involved in the formation and progression of human
cancers emerged in cancer treatment. However, the lack of
ubiquitously expressed tumor-specific antigens or receptors on
cancer cells and the geno/phenotypic heterogeneity of tumors
limited the application of such methods. During the past few
years, scientists have developed plasma membrane-targeted
molecular assemblies reaching cancer cell selectivity.
In 2014, the Xu lab reported the first plasma membrane-
targeted molecular assembly that selectively targeted cancer
cells. In that research, cancer biomarkers, surface and secretory
alkaline phosphatases (ALPs) dephosphorylate a small D-peptide
derivative PM1 in pericellular space triggering molecular
assembly into nanonets around cancer cells that overexpress
phosphatase (Figure 1).5 By blocking cellular mass exchange
between the cancer cells with their environment, the nanonets
significantly decrease the cancer cell viability. Carbonic anhy-
drase (CA) IX overexpressed on cell membranes of hypoxic
tumors was also applied in enzyme-assisted plasma-membrane
targeted molecular assembly. The Chen lab coupled CA IX
inhibitor 4-(2-aminoethyl)benzenesulfonamide (ABS) with
D-peptide derivatives obtaining molecule PM2 that self-assem-
ble on hypoxic cancer cell surfaces causing intracellular acid
vesicle damage and blocking protective autophagy (Figure 1).6
Inspired by the Xu lab’s pioneering concept of using cellular
enzymes to trigger the release of activated compounds that can
form molecular assembly structures in situ in the vicinity of the
initiating enzymes, our lab designed and synthesized a rutheni-
um-complex-based D-peptidic molecule PM3. Instead of target-
ing the whole membrane, the Ru-complex PM3 selectively
initiates molecular assembly into nanofibrils on lipid rafts
(Figure 1),7 which substantially increases the sub-cellular
resolution of molecular assembly technologies. The lipid-raft-
targeted molecular assembly suppresses cervical cancer cell
migration and invasion via actin cytoskeleton mediated bio-
physical regulations leading to potentially precise control of cell
response. Our lab later synthesized an expanded π-conjugation-
based molecular precursor PM4, which has an extremely high
rigidity and a long hydrophobic length that is comparable to the
hydrophobic width of plasma membrane.8 Guided by the ALPs
in cancer environment, the soluble precursors transform into
hydrophobic monomers forming assemblies inserted into the
fluid phase of the plasma membrane exclusively (Figure 1),
which destroys the selective membrane permeability gradually
resulting into cancer cell death.
In 2020, our lab reported integrin-ligand binding induced
molecular assembly on cancer cell membrane (Figure 2). A self-
assembling integrin ligand PM5 was synthesized by coupling
integrin β1 ligand YIGSR with several aromatic amino acids.9
Upon cell culture, these molecules selectively form nanofibrous
microdomains via molecular assembly on the apical membrane
of glioma cells inhibiting their migration and invasion without
introducing cytotoxicity. We also reported a molecular design for
integrin and heparan sulfate dual-targeting molecular assembly
on cancer cellmembrane. In this research, we decorated IKLLI, a
ligand of both integrin β1 and heparan sulfate, with aromatic
amino acids to obtain self-assembling ligand PM6. Molecule
PM6 selectively targets cancer cell membrane by forming
nanofibrils on the plasma membrane (Figure 2). Without induc-
ing toxicity, the nanostructures suppress cancer metastasis. These
studies demonstrate a new membrane-targeted molecular assem-
Figure 1. Schematic presentation of enzyme-assisted plasma
membrane-targeting molecular assembly and the chemical
structures of precursor molecules.
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bly via protein-ligand binding interaction which is different from
enzyme-assisted self-assembly strategy.
ER-targeted Molecular Assembly
Endoplasmic reticulum (ER) is an elaborate network
membrane that extends throughout the cell. The ER is closely
associated with plasma membrane, mitochondria, Golgi, vac-
uoles, peroxisomes, late endosomes and lysosomes for coordi-
nation activities. The functions of ER include protein synthesis
that occurs in the rough ER, lipid metabolism that occurs in the
smooth ER, and detoxification of the cell. The capacity of the
ER to process proteins is limited. The accumulation of unfolded
and misfolded proteins can lead to ER stress initiating apoptosis
which has been encountered as an anticancer strategy.10
Inhibiting components of the unfolded protein response with
small molecule inhibitors is one of the most common approaches
of drug discovery as anti-tumor agents.
The Xu lab reported an ER-targeted design of molecular
assembly using phosphotetrapeptide ER1. Attaching an L-amino
acid at the C-terminal of a D-tripeptide result in crescent-shaped
molecular assemblies via ALP triggered dephosphorylation.11
The crescent-shaped nanostructures disrupt plasma membrane
integrity to enable further accumulation on the ER causing ER
stress and activating the caspase signaling cascade for cell death
(Figure 3). Based on this design concept, the Xu lab integrated
the ER-targeting peptide building block with naproxen­a non-
steroidal anti-inflammatory drug (NSAID) and ligand of cyclo-
oxygenase-2 (COX-2). The phosphatase triggered molecular
assemblies on ER enable the sequestration of COX-2 and
protein-tyrosine phosphatase 1B (PTP1B) on ER demonstrating
a new strategy for modulating protein-protein interactions.12
Inspired by the research on micelles, liposomes, and
polymeric particles that targeted the ER, the Basu lab designed
and synthesized triazine-based small molecule ER2 containing a
fluorescent dansyl group as the ER targeting moiety that formed
a self-assembled hexameric rosette structure through Watson-
Crick based H-bonding with 5-fluorouracil leading to the
formation of hitherto spherical nanoparticles. These nanoparti-
cles internalized into HeLa cervical cancer cells by micro-
pinocytosis and specifically localized into the ER to induce ER
stress (Figure 3).13
Our lab recently reported a carboxylesterase (CES)-facili-
tated ER-targeting molecular assembly.14 We designed and
synthesized an N-hydroxylethyl peptide by coupling naphtha-
lene-Phe-Phe with ethanolamine. By protecting the hydroxyl
group using a fluorescent coumarin derivative via an ester
linkage, a precursor molecule ER3 was obtained forming sparse
aggregates via molecular assembly in water. After passive
diffusion, aggregates entered cytoplasm and were hydrolyzed
into N-hydroxylethyl peptide and coumarin derivative by
intracellular carboxylesterase (CES). The hydrolyzed product
molecules co-assembled into nanofibrils around the ER inducing
ER dilation (Figure 3). In this research, the comparison of ER3
with the other two self-assembling molecules also indicated that
vesicle-shaped assemblies or sparse irregular-shaped aggregates
facilitate passive diffusion into cytosol approaching the ER.
Mitochondria-targetingMolecular Assembly
Besides oxidative phosphorylation, central carbon metabo-
lism, and the biosynthesis of intermediates for cell growth, the
most notably key roles that mitochondria play in the cell,
mitochondria participate in nearly all aspects of cell function
and fate.15 They are the powerhouse of cell, and the suicidal
weapon store inside the cell. Therefore, inhibiting tumor-specific
alterations of the mitochondrial metabolism or stimulating
mitochondrial membrane permeabilization are considered as
promising therapeutic approaches.16 The development of small
molecule drugs mainly focused on targeting permeability
transition pore complex (PTPC) in the mitochondrial outer
membrane or inducing the overproduction of reactive oxygen
species (ROS). Because directly targeting mitochondria has the
potential to bypass resistance mechanisms, increasing the level
of selectively of mitochondrially-targeted anticancer agents is a
promising avenue for further research.
Figure 2. Schematic presentation of integrin-targeted molec-
ular assembly and integrin/heparan sulfate dual-targeting
molecular assembly and the chemical structures of self-
assembling ligands.
Figure 3. Schematic presentation of three different designs of
ER-targeting molecular assembly and the chemical structures of
precursor molecules.
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In 2016, the Xu lab reported a bioinspired molecular process
that selectively generated the assemblies of redox modulators
selectively targeting the mitochondria of cancer cells.17 By
attaching triphenyl phosphonium (TPP)­a facile molecular motif
for targeting the mitochondrial matrix,18 to a pair of enantio-
meric, phosphorylated tetrapeptide derivatives, a pair of pre-
cursors MT1L and MT1D were synthesized. Upon dephosphor-
ylation catalyzed by ectophosphatases overexpressed on cancer
cells, the precursor molecules self-assemble to form nanoscale
assemblies only on the cancer cell surface. Following a caveola/
raft-dependent endocytosis, these nanoscale assemblies enter
into the cancer cell, escape from the lysosome, induce dysfunc-
tion of mitochondria and result in cell death (Figure 4). Later,
the Ryu lab synthesized MT2 which consisted of diphenyl-
alanine as a β-sheeting-forming building block, TPP, and pyrene
as a fluorescent probe. MT2 favorably accumulated in the
mitochondria of cancer cells leading to self-assembly forming
nanofibrils (Figure 4). The fibrils destroyed the mitochondrial
membrane and activated the intrinsic apoptotic pathway against
cancer cells.19
Besides using TPP, the Xu lab found that conjugating a
hydrophilic FLAG motif (DDDDK) to self-assembling motifs
afforded precursors MT3 assembling into micelles.20 After
being taken up by cells, upon the enterokinase (ENTK)
catalyzed cleavage of the FLAG, the micelles turn into nano-
fibers to locate mainly at mitochondria. Besides being applicable
as drug carriers, further engineering of the MitoFlag in MT4
facilitated the trafficking of a histone protein (H2B) to the
mitochondria in cancer cells selectively,21 which is potentially
applicable in manipulating inter-organelle communications
(Figure 5). Replacing the self-assembling motifs with a lipid-
like moiety (NH2-Glu-(C16)2), MT5 was obtained maintaining
the same self-assembly performance forming micelles for
mitochondria-targeted drug delivery.22
Dual-targeting Molecular Assembly
Combination treatments are the current trends leading
anticancer drug research and development. Compared to single
drugs, drug combinations that target multiple biological path-
ways take advantage of synergistic killing and decrease the risk
of relapse. Regarding the R&D cost, the greatest efforts on the
development of combination therapy are concentrated on the
screening of small molecule drug combinations. The promise of
nanomedicine in the fight against cancer motivates the enthu-
siasm to elevate the development of nanotechnology for com-
bination therapy. And the combination of molecular assembly in
cell milieu is proved to be a promising approach.
Our lab developed a strategy of producing small self-
assembling molecules for dual-targeting combination treatment.
As demonstrated in Figure 6, chlorambucil, a small molecule
chemotherapy medication that alkylates and crosslinks DNA
was coupled with ER-targeting self-assembling motifs (L and
D-version) via diester bonds to obtain DT1L and DT1D. Both
molecules self-assemble into nanovesicles that easily enter into
the cells.23 Upon the hydrolysis by CES that is commonly
Figure 4. Schematic presentation of TPP-based mitochondria-
targeting molecular assembly and the chemical structures of
candidate molecules.
Figure 5. Schematic presentation of MitoFlag-based mito-
chondria-targeting molecular assembly and the chemical struc-
tures of candidate molecules.
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expressed in tumor tissue, chlorambucil is released to damage
DNA, and the self-assembling motifs are released to form nano-
fibrils on ER inducing ER stress (Figure 6). The dual-targeting
design reached higher anticancer efficacy than single-targeting
drug.
We also demonstrated another strategy of dual-targeting
molecular assembly design by co-administration of a pair of
homochiral-peptide derivatives targeting two different sub-
organelles for molecular assembly. Naphthalene-PTyr-Phe-Lys-
taurine and naphthalene-Ptyr-phe-lys-taurine were selected to
couple with the aggregation-induced emission (AIE) motif­
boron diketone on the side chain of lysine obtaining DT2L and
DT2D. Mediated by the PLAP enzyme on cancer cellmembrane,
plasma membrane and lysosome dual-targeted molecular assem-
blies introduces a synergistic anti-cancer effect with amplified
efficacy (Figure 6).24 Such research opens up new opportunities
for the design of combination therapy via the application of
nanotechnologies.
Conclusion
Instead of acting solely as pharmaceutical drug carriers,
scientists have discovered more functions of molecular assem-
blies by constructing nano-biointerfaces to facilitate interface
communications between synthetic nano/microstructures and
cellular organelles. Considering the requirement of noninvasive
in-situ self-assembly tracking in vitro/in vivo, small organic
fluorophore, for example 7-nitrobenzofurazan (NBD), coumarin
derivatives, pyrene, BODIPY, etc.; transition metal complex,
for example ruthenium (II) and iridium (III) with chelating
N-heterocyclic ligands; and expanded π-conjugation-based
molecules have been used in molecular design to make self-
assembly illuminated in biological systems. Besides considering
the excitation/emission properties of the fluorophores for bio-
compatibility, as a hydrophobic building block or three-dimen-
sional scaffold, the fluorophores are also applied to regulate
the overall hydrophilicity/hydrophobicity, charge density of
the target molecules facilitating the formation self-assembled
morphologies with different surface ‘function’. Various possi-
bilities are generated via molecular assembly instructed interface
interactions including the control of membrane permeability, the
regulation of membrane associated proteins, and the adaptive
remodeling of the membrane structures. As summarized here,
most developments were made on targeting sub-cellular organ-
elles with large membrane structures that are easily targeted by
nano/microstructures exhibiting powerful anti-cancer effect.
The design of molecular assembly targeting small compartments
with higher resolution on plasma membrane and intracellular
organelles of smaller size, like endo/lysosomes and cytoskele-
ton filaments, is still underdeveloped. Advancing the controlla-
bility of molecular assembly in both morphology, selectivity,
and functionality via bottom-up approaches is desired in future
study.
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